23.94%| YTD | 1Yr | 3Yr | 5Yr | 10Yr | |
| Fund | 23.94 | 26.14 | 2.33 | 6.86 | 8.84 |
| Classification | 14.59 | 17.02 | -1.33 | 3.01 | 6.37 |
| Index (S&P 500) | 20.90 | 21.30 | -6.10 | 0.30 | -0.70 |
| % Rank in Class (1-best,100=worst) | 18 | 19 | 8 | 12 | 21 |
| Investment Objective: | Health/Biotech |
|---|---|
| Net Assets ($Mil) | NA |
| Inception Date: | 12/29/95 |
| Manager Name, Tenure | Kris H. Jenner, 2000 |
| Expense Ratio: | 0.86% |
|
Sales Charge:
Load Type:
|
No Load 0.00% 0.00% |
| Company Name | Symbol | % Net Assets |
|---|---|---|
| Gilead Sciences Inc | GILD | 6.28 |
| Alexion Pharm | ALXN | 3.92 |
| Baxter International Inc | BAX | 3.39 |
| Wyeth | WYE | 2.78 |
| Teva Pharmaceutical Industries Ltd | TEVA | 2.66 |
| Medco Health Sol | MHS | 2.51 |
| Henry Schein | HSIC | 2.44 |
| Roche Holding Ag | RHHVF | 2.37 |
| Amgen | AMGN | 2.09 |
| Wellpoint Inc | WLP | 2.08 |
| % of Total Holdings | 30.52 | |